Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT Augmentation of Naltrexone/Bupropion in BED and Obesity
NCT03063606Phase 3Completed
- Sponsor
- Yale University
- Start
- Sep 2017
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial (2 arms), sponsored by Yale University. Primary endpoints: Binge Eating Frequency at 4 months and Change in Body Mass Index at 4 months. Started Sep 2017; status: completed.
Beyond the preview
Go deeper on NCT03063606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063606.